6 results match your criteria: "Neocare Hospital[Affiliation]"
Early erythropoiesis-stimulating agents in preterm or low birth weight infants.
Cochrane Database Syst Rev
February 2020
Neocare Hospital, Neonatal Intensive Care Unit, Mumbai Naka, Nashik, Maharashtra, India, 422002.
Background: Preterm infants have low plasma levels of erythropoietin (EPO), providing a rationale for the use of erythropoiesis-stimulating agents (ESAs) to prevent or treat anaemia and to provide neuro protection and protection against necrotising enterocolitis (NEC). Darbepoetin (Darbe) and EPO are currently available ESAs.
Objectives: To assess the effectiveness and safety of ESAs (erythropoietin (EPO) and/or Darbe) initiated early (before eight days after birth) compared with placebo or no intervention in reducing red blood cell (RBC) transfusions, adverse neurological outcomes, and feeding intolerance including necrotising enterocolitis (NEC) in preterm and/or low birth weight infants.
Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
Cochrane Database Syst Rev
February 2020
University of Toronto, Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation, Toronto, Canada.
Background: Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anaemia.
Objectives: To assess the effectiveness and safety of early versus late initiation of EPO in reducing red blood cell (RBC) transfusions in preterm and/or low birth weight (LBW) infants.
Search Methods: The standard search of the Cochrane Neonatal Review Group (CNRG) was performed in 2006 and updated in 2009.
Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Cochrane Database Syst Rev
January 2020
University of Toronto, Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation, Toronto, Canada.
Background: Preterm infants have low plasma levels of erythropoietin (EPO), providing a rationale for the use of erythropoiesis-stimulating agents (ESAs) to prevent or treat anaemia. Darbepoetin (Darbe) and EPO are currently available ESAs.
Objectives: To assess the effectiveness and safety of late initiation of ESAs, between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm or low birth weight infants.
Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Cochrane Database Syst Rev
February 2019
Neonatal Intensive Care Unit, Neocare Hospital, Mumbai Naka, Nashik, Maharashtra, India, 422002.
Background: Preterm infants have low plasma levels of erythropoietin (EPO), providing a rationale for the use of erythropoiesis-stimulating agents (ESAs) to prevent or treat anaemia. Darbepoetin (Darbe) and EPO are currently available ESAs.
Objectives: To assess the effectiveness and safety of late initiation of ESAs, between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm or low birth weight infants.
Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
Cochrane Database Syst Rev
April 2014
Neonatology, Dr. Aher's Neocare Hospital, Near Tusakhre Lawns, Mumbai Naka, Nashik, Maharashtra, India, 422002.
Background: Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anaemia.
Objectives: To assess the effectiveness and safety of late initiation of erythropoietin (EPO) between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm and/or low birth weight infants.
Search Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL in July 2013.
Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
Cochrane Database Syst Rev
October 2012
Neonatology, Dr. Aher’s Neocare Hospital, Nashik, India.
Background: Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anaemia.
Objectives: To assess the effectiveness and safety of early versus late initiation of EPO in reducing red blood cell (RBC) transfusions in preterm and/or low birth weight (LBW) infants.
Search Methods: The standard search of the Cochrane Neonatal Review Group (CNRG) was performed in 2006 and updated in 2009.